How big is HOOKIPA Pharma, Inc.?

As of Jun 18, HOOKIPA Pharma, Inc. has a market capitalization of 15.97 million, with net sales of 9.34 million and a net profit of -73.31 million over the latest four quarters. The company reported shareholder's funds of 51.21 million and total assets of 82.55 million as of Dec 24.

Market Cap: As of Jun 18, HOOKIPA Pharma, Inc. has a market capitalization of 15.97 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, HOOKIPA Pharma, Inc. reported net sales of 9.34 million and a net profit of -73.31 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 51.21 million and total assets of 82.55 million.

What does HOOKIPA Pharma, Inc. do?

HOOKIPA Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. As of March 2025, it has a market cap of $15.97 million, with net sales of $2 million and a net loss of $15 million.

Overview: <BR>HOOKIPA Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products to prevent and cure infectious diseases and cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 15.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.18 <BR>Return on Equity: -198.89% <BR>Price to Book: 0.47<BR><BR>Contact Details: <BR>Address: 430 East 29Th Street, 14Th Floor, NEW YORK NY: 10016-8367 <BR>Fax: 1 302 6555049 <BR>Website: https://www.hookipapharma.com/

Should I buy, sell or hold HOOKIPA Pharma, Inc.?

Who are in the management team of HOOKIPA Pharma, Inc.?

As of March 2022, the management team of HOOKIPA Pharma, Inc. includes Prof. Jan van de Winkel (Chairman), Mr. Joern Aldag (CEO), Dr. Reinhard Kandera (CFO), and several independent directors. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of HOOKIPA Pharma, Inc. includes the following individuals:<BR><BR>- Prof. Jan van de Winkel, Independent Chairman of the Board<BR>- Mr. Joern Aldag, Chief Executive Officer and Director<BR>- Dr. Reinhard Kandera, Chief Financial Officer and Director<BR>- Dr. Jean-Charles Soria, Director<BR>- Dr. David Kaufman, Independent Director<BR>- Mr. Michael Kelly, Independent Director<BR>- Dr. Christoph Lengauer, Independent Director<BR>- Ms. Julie O Neill, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is HOOKIPA Pharma, Inc. technically bullish or bearish?

As of September 11, 2025, HOOKIPA Pharma, Inc. shows a mildly bearish trend with daily moving averages indicating weakness, despite a mildly bullish MACD, and has significantly underperformed the S&P 500 with a year-to-date return of -55.20%.

As of 11 September 2025, the technical trend for HOOKIPA Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the weekly KST also showing bearish signals. While the MACD is mildly bullish on both weekly and monthly time frames, the overall indicators suggest weakness. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -55.20% versus the S&P 500's 12.22%, and a one-year return of -80.51% compared to the S&P 500's 17.14%.